Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933843 | 0.74 | — | — | |
| SCHEMBL10851 | 0.70 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTPDK1HTT | |
| SCHEMBL3932088 | 0.67 | — | — | |
| SCHEMBL80737 | 0.67 | GPR3 (0.35) | ALDH1A1MAPTHPGD | |
| SCHEMBL3831848 | 0.67 | — | — | |
| SCHEMBL3940440 | 0.67 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTPDK1HTT | |
| SCHEMBL286319 | 0.67 | NUDT1 (0.33) | — | |
| SCHEMBL88856 | 0.64 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTTGFBR1HTT | |
| SCHEMBL29599675 | 0.64 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTTGFBR1HTT | |
| SCHEMBL449767 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501698-B1 | FLUORINATED MONOMERS, OLIGOMERS AND POLYMERS FOR USE IN ORGANIC ELECTRONIC DEVICES | NAT RES COUNCIL CANADA (CA) | 2018-04-25 | — | — | EP | claimed |
| EP-2828262-A1 | IMIDAZOTRIAZINONE COMPOUNDS | Forum Pharmaceuticals Inc. (US) | 2015-01-28 | — | — | EP | claimed |
| US-8927684-B2 | Fluorinated monomers, oligomers and polymers for use in organic electronic devices | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2015-01-06 | — | — | US | claimed |
| WO-2013142269-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | WO | claimed |
| US-20120232237-A1 | Fluorinated Monomers, Oligomers and Polymers for Use in Organic Electronic Devices | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2012-09-13 | — | — | US | claimed |
| EP-4370520-A1 | TWO DIMENSIONAL BENZO[4,5]IMIDAZO[2,1-A]ISOINDOLE INCORPORATED NON-FULLERENE ELECTRON ACCEPTORS FOR ORGANIC PHOTOVOLTAIC DEVICES | National Research Council of Canada (CA) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023283728-A1 | TWO DIMENSIONAL BENZO[4,5]IMIDAZO[2,1-A]ISOINDOLE INCORPORATED NON-FULLERENE ELECTRON ACCEPTORS FOR ORGANIC PHOTOVOLTAIC DEVICES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022128850-A1 | NOVEL ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-06-23 | — | — | WO | disclosed |
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| EP-2501698-B1 | FLUORINATED MONOMERS, OLIGOMERS AND POLYMERS FOR USE IN ORGANIC ELECTRONIC DEVICES | NAT RES COUNCIL CANADA (CA) | 2018-04-25 | — | — | EP | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
| US-6645969-B1 | Antiproliferative, anticarcinogenic, and antiinflammatory agents; treatment of leukemia, psoriasis, bone disorders, and atherosclerosis | AVENTIS PHARMACEUTICALS INC. | 2003-11-11 | — | — | US | disclosed |
| US-RE37650-E1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | AVENTIS PHARMACETICAL PRODUCTS, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-0871448-A4 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE POULENC RORER PHARMA (US) | 1999-12-29 | — | — | EP | disclosed |
| CN-1202800-A | Herbicidal composition | NOVARTIS AG (CH) | 1998-12-23 | — | — | CN | disclosed |
| EP-0871448-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| CN-1144526-A | Thiazolidines and oxazolidines substituted by pyridine ring and their use a hypoglycemic agents | NISSAN CHEMICAL IND LTD (JP) | 1997-03-05 | — | — | CN | disclosed |
| WO-1995015758-A1 | ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE12, PDE4A | ALDH1A1 779/4885KDM4E 921/4885MAPT 3164/4885 |
| US-20120232237-A1 | Fluorinated Monomers, Oligomers and Polymers for Use in Organic Electronic Devices | NR1I2, NR1I3, NR2C2 | ALDH1A1 3171/4885KDM4E 3723/4885MAPT 2770/4885 |
| US-20040014774-A1 | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase | CSF1R, CSF3R, FLT3 | ALDH1A1 3893/4885KDM4E 2126/4885MAPT 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.